Primary Site >> Colorectal Cancer
Gene >> MT1E
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: [Phase I clinical study of CPT-11. Research group of CPT-11]. PMID: 2404454 |
Ref: Phase I trial of postoperative 5-FU, radiation therapy, and high dose leucovorin for resectable rectal cancer. PMID: 1727111 |
Ref: In vivo antitumor activity of hexamethylmelamine against human breast, stomach and colon carcinoma xenografts. PMID: 7559101 |
Ref: [LY188011 phase I study. Research Group of Gemcitabine (LY188011)]. PMID: 8687215 Ref: [Nedaplatin]. PMID: 8712835 |
Ref: Radioimmunotherapy of small volume disease of colorectal cancer metastatic to the liver: preclinical evaluation in comparison to standard chemotherapy and initial results of a phase I clinical study. PMID: 10541369 |
Ref: ZD-9331 AstraZeneca. PMID: 11249590 |
Ref: Addition of oxaliplatin to continuous fluorouracil, l-folinic acid, and concomitant radiotherapy in rectal cancer: the Lyon R 97-03 phase I trial. PMID: 11331322 Ref: Phase I trial of sequential administration of raltitrexed (Tomudex) and 5-iodo-2'-deoxyuridine (IdUrd). PMID: 11432631 |
Ref: A phase I study of oral UFT given concomitantly with standard preoperative radiotherapy for rectal cancer. PMID: 15473585 |
Ref: [Phase I study of CPT-11 and continuous 5-FU / l-leucovorin combination therapy(modified AIO regimen)in patients with metastatic colorectal cancer]. PMID: 18931571 |
Ref: Apoptotic sensitivity of colon cancer cells to histone deacetylase inhibitors is mediated by an Sp1/Sp3-activated transcriptional program involving immediate-early gene induction. PMID: 20068171 Ref: A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol. PMID: 20953860 |
Ref: Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors. PMID: 21131552 |
Ref: A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors. PMID: 25212606 Ref: Phase I dose-escalation trial of the oral investigational Hedgehog signaling pathway inhibitor TAK-441 in patients with advanced solid tumors. PMID: 25501576 |
Ref: Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors. PMID: 26831715 Ref: Phase I study of pre-operative continuous 5-FU and sorafenib with external radiation therapy in locally advanced rectal adenocarcinoma. PMID: 26861740 Ref: A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors. PMID: 26864210 Ref: Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer. PMID: 27026198 Ref: Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin. PMID: 27542211 |
Ref: A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer. PMID: 29067643 |